EX-FILING FEES 8 ea021780801ex-fee_cero.htm FILING FEE TABLE

Exhibit 107

 

Calculation of Filing Fee Tables

 

Form S-1

(Form Type)

 

CERo Therapeutics Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

 

    Security
Type		   Security
Class
Title		     Fee
Calculation
or Carry
Forward
Rule		     Amount
Registered(1)		   Proposed
Maximum
Offering
Price Per
Unit		   Maximum
Aggregate
Offering
Price		     Fee Rate     Amount of
Registration Fee		     Carry
Forward Form
Type		     Carry
Forward
File Number		     Carry
Forward
Initial
effective
date		     Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward		  
Newly Registered Securities
                                                                     
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       57,670,954 (3)  $ 0.0876 (2) $ 5,028,907.19       0.00015310     $ 769.93                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       9,182,934 (4) $ 0.0876 (2) $ 800,751.84       0.00015310     $ 122.60                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       70,739,367 (5) $ 0.0876 (2) $ 6,168,472.80       0.00015310     $ 944.39                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       436,683,678 (6) $ 0.0876 (2) $ 38,078,816.72       0.00015310     $ 5,829.87                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       250,000 (7) $ 0.0876 (2) $ 21,800.00       0.00015310     $ 3.34                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share       457(c)       75,000,000 (8) $ 0.0876 (2) $ 6,540,000.00       0.00015310     $ 1001.27                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share, underlying Warrants       457(c)       8,175,166 (9) $ 0.0876 (2) $ 712,874.48       0.00015310     $ 109.14                                  
Fees to Be
Paid		   Equity     Common Stock, par value $0.0001 per share, underlying Warrants       457(c)       55,861,651 (10) $ 0.0876 (2) $ 4,871,135.97       0.00015310     $ 745.77                                  
Carry Forward Securities
                                                                                         
Carry
Forward
Securities		   —     —       —       —           —                       —       —       —       —  
    Total Offering Amounts     $ 62,222,759.00             $ 9,526.30                                  
    Total Fees Previously Paid                       —                                  
    Total Fee Offsets                       —                                  
    Net Fee Due                     $ 9,526.30                                  

   

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), there is also being registered hereby such indeterminate number of additional shares of common stock, par value $0.0001 per share (“Common Stock”), of CERo Therapeutics Holdings, Inc. (the “Company”) as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions.
(2) Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of Common Stock on the Nasdaq Global Market on October 17, 2024. This calculation is in accordance with Rule 457(c) of the Securities Act.
(3) Represents shares of Common Stock issuable upon the conversion of shares of our Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), purchased by certain investors pursuant to the Amended and Restated Securities Purchase Agreement, dated as of February 14, 2024, by and among Legacy CERo, PBAX and such investors (the “First Securities Purchase Agreement”).
(4) Represents shares of Common Stock issuable upon the conversion of shares of our Series B Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”), purchased by certain investors pursuant to the Securities Purchase Agreement, dated as of March 29, 2024, by and among us and such investors.
(5) Represents shares of Common Stock issued upon the conversion of shares of our Series A Preferred Stock and Series B Preferred Stock, at effective conversion prices ranging from $0.0647 to $0.2024.
(6) Represents shares of Common Stock issuable upon the conversion of shares of our Series C Preferred Stock, par value $0.0001 per share, purchased by certain investors pursuant to the Securities Purchase Agreement, dated as of September 25, 2024, by and among us and such investors (the “Third Securities Purchase Agreement”).
(7) Represents shares of Common Stock issued to a stockholder in a reallocation of shares in connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated as of June 4, 2023, as amended by Amendment No. 1, dated February 5, 2024 and Amendment No. 2, dated February 13, 2024, by and between Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc.
(8) Represents shares of our Common Stock issuable to a service provider.
(9) Represents shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock, which were sold to certain investors pursuant to the Third Securities Purchase Agreement.
(10) Represents shares of Common Stock issuable upon the exercise of outstanding warrants to purchase shares of our Series A Preferred Stock, which were sold to certain investors pursuant to the First Securities Purchase Agreement, and conversion of the underlying shares of Series A Preferred Stock into Common Stock.